Novel Chemically-modified DNAzyme targeting Integrin alpha-4 RNA transcript as a potential molecule to reduce inflammation in multiple sclerosis
Open Access
- 9 May 2017
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 1-8
Abstract
Integrin alpha-4 (ITGA4) is a validated therapeutic target for multiple sclerosis (MS) and Natalizumab, an antibody targeting ITGA4 is currently approved for treating MS. However, there are severe side effects related to this therapy. In this study, we report the development of a novel DNAzyme that can efficiently cleave the ITGA4 transcript. We designed a range of DNAzyme candidates across various exons of ITGA4. RNV143, a 30mer arm-loop-arm type DNAzyme efficiently cleaved 84% of the ITGA4 mRNA in human primary fibroblasts. RNV143 was then systematically modified by increasing the arm lengths on both sides of the DNAzymes by one, two and three nucleotides each, and incorporating chemical modifications such as inverted-dT, phosphorothioate backbone and LNA-nucleotides. Increasing the arm length of DNAzyme RNV143 did not improve the efficiency however, an inverted-dT modification provided the most resistance to 3′ → 5′ exonuclease compared to other modifications tested. Our results show that RNV143A could be a potential therapeutic nucleic acid drug molecule towards the treatment for MS.Keywords
This publication has 33 references indexed in Scilit:
- RNA-Based Therapeutics: Current Progress and Future ProspectsChemistry & Biology, 2012
- The safety and side effects of monoclonal antibodiesNature Reviews Drug Discovery, 2010
- Locked Nucleic Acids: Promising Nucleic Acid Analogs for Therapeutic ApplicationsChemistry & Biodiversity, 2010
- DNAzymes and their therapeutic possibilitiesInternal Medicine Journal, 2009
- DNAzyme-Mediated Silencing of Ornithine DecarboxylaseBiochemistry, 2005
- A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with aidsAmerican Journal of Ophthalmology, 2002
- Comparative Study of DNA Enzymes and Ribozymes against the Same Full-length Messenger RNA of the Vanilloid Receptor Subtype IJournal of Biological Chemistry, 2002
- The Influence of Arm Length Asymmetry and Base Substitution on the Activity of the 10-23 DNA EnzymeAntisense and Nucleic Acid Drug Development, 2000
- Mechanism and Utility of an RNA-Cleaving DNA EnzymeBiochemistry, 1998
- Protein Enhancement of Hammerhead Ribozyme CatalysisScience, 1993